AQUAVAN® (fospropofol disodium) Injection + Midazolam HCl
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colonoscopy
Conditions
Colonoscopy, Colonic Polyps
Trial Timeline
Jul 1, 2005 → Sep 1, 2005
NCT ID
NCT00125424About AQUAVAN® (fospropofol disodium) Injection + Midazolam HCl
AQUAVAN® (fospropofol disodium) Injection + Midazolam HCl is a phase 2/3 stage product being developed by Eisai for Colonoscopy. The current trial status is completed. This product is registered under clinical trial identifier NCT00125424. Target conditions include Colonoscopy, Colonic Polyps.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00125424 | Phase 2/3 | Completed |
Competing Products
7 competing products in Colonoscopy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| fospropofol disodium | Eisai | Phase 3 | 77 |
| fospropofol disodium | Eisai | Phase 2 | 52 |
| fospropofol disodium | Eisai | Phase 2 | 52 |
| HSK3486 + Propofol | Haisco Pharmaceutical Group | Phase 2 | 49 |
| HSK3486 + Propofol | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Methylene Blue MMX 25 mg modified release tablets | Cosmo Pharmaceuticals | Phase 2 | 47 |
| Polyethylene glycol 4000 + Macrogol 3350 plus ascorbic acid | Rafael Holdings | Approved | 77 |